Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials
Pooled result · Percentage change in LDL-C from baselineResult — go to the resultEstimated treatment difference - 64.02 % 95% CI - 68.08%, - 59.96%Authors' conclusion
Tafolecimab 450 mg Q4W demonstrated a superior lipid-lowering efficacy and favorable safety profile compared to placebo. This suggests it could be a promising new treatment option for Chinese patients with T2D and hypercholesterolemia.
Study context
- Population
- Chinese patients with T2D and hypercholesterolemia
- Comparison
- Tafolecimab 450 mg Q4W vs placebo
- Outcome
- Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline
- Follow-up
- Week 12
Methodological detailspooled data, placebo-controlled
- Pooled data
- Placebo-controlled
Pooled result
As reported in the abstract
Estimated treatment difference
- 64.02 %
95% CI - 68.08%, - 59.96%
P < 0.0001
Further pooled results
| Outcome | P value |
|---|---|
| LDL-C reduction >50% and LDL-C <1.4 mmol/LSignificantly higher proportion with tafolecimab | P < 0.0001 |
| LDL-C <1.8 mmol/L · week 12Significantly greater proportion with tafolecimab | P < 0.0001 |
| Percentage change in TG, non-HDL-C, apo B and Lp(a) · baseline to week 12Significant reductions with tafolecimab | all P < 0.001 |
Safety
- Incidence of adverse events generally similar between the two groups
Original publication
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials. Cardiovasc Diabetol. Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →